A new daily MS pill is seeking regulatory approval in 2026

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain.

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

A study shows trametinib and rapamycin, two drugs used for cancer treatment in humans, increased mouse lifespan when used together. The medications delayed the onset of cancer and reduced chronic inflammation, results that will be explored in future research.

The clinical trials are designed to determine whether experimental CRISPR-related therapies are safe and effective. The majority of trials involve treatments for blood disorders, including beta thalassemia.

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

University of Southern California researchers have launched a phase 2b clinical trial of a stem cell implant designed to restore vision in people with advanced dry macular degeneration. Patients will be randomized to receive the stem cell implant or a simulated procedure and placebo implant. This type of larger, second-stage clinical trial is designed to confirm efficacy and dosing and to look for side effects. It's one of the stages that precedes the US Food & Drug Administration approval of a device.

Victoria Gray was the first patient to receive a CRISPR-based therapy, which eliminated her symptoms and restored her health. The therapy's initial cost of $2.2M has kept it out of reach of many patients.

A new class of antibiotics had not been discovered in more than 50 years—until late 2023, when MIT researchers announced a new antibiotic called Zosurabalpin. In animal testing, Zosurabalpin was able to treat at least one type of superbug. While the drug still needs to go through clinical trials, it is a significant advance at a time when new antibiotics are in great demand.

A small number of lupus patients have remained in complete remission for years after undergoing an experimental CAR-T cell therapy that seems to eliminate enough B cells to fuel a "deep reset" of the immune system. CAR-T therapy is also being used experimentally to treat MS, myositis, and other autoimmune disorders.

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

This later-stage clinical trial, in Chicago and Taiwan, evaluates the efficacy and safety of a new cellular therapy that may be swapped in for immunosuppressing drugs among kidney transplant recipients. The study randomizes people to either receive standard immunosuppressants or this cellular therapy and fewer immunosuppressants. It only includes kidney transplant recipients receiving organs from live donors so transplant surgery timing won't hinge on the unpredictable schedule of performing surgery and follow-up care when a donor dies.

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

The change came a decade after the FDA added the label. Recent work, including a gold-standard randomized trial, found that men receiving the products had similar cardiovascular risk levels as men taking placebo products. Testosterone, however, may hold other health risks, including infertility.

Clinical data from a couple patients in 2025 indicated that one experimental CAR-T therapy called rese-cel was able to genetically reprogram T cells to eliminate certain problematic immune B cells that were causing the condition. The therapy reduced skin thickening and allowed the patients to halt using immunosuppressive medications and steroids.

The US database of clinical trials listed more than 1,400 macular degeneration trials in early 2026. That doesn't mean every trial is recruiting, but it does indicate there is significant interest in this medical condition.

The country green lighted the treatments for July 1, 2023, onward, with MDMA—ectasy—as a post-traumatic stress disorder treatment, and psilocybin—magic mushrooms—as an option for people with treatment-resistant depression.

The agency proposed a new rule in 2023 to make it explicit that these types of tests are devices under existing law and clarify that that the agency could move to regulate them. They finalized a regulatory change in 2024 that added the words "including when the manufacturer of these products is a laboratory" to an existing law, but a federal district court vacated that edit in March 2025—returning the law to as it was before.

Clinical trials showed a 44% reduction in risk for recurrence of SAD for those who took the drug compared to a placebo group. Bupropion is a norepinephrine–dopamine reuptake inhibitor, which increases dopamine (other common antidepressants, known as selective serotonin reuptake inhibitors, sometimes can suppress dopamine, but not always).

This new medication, called Palforzia, is designed to stave off severe reactions from accidental peanut exposures with a daily dose that is increased over time under an allergist’s supervision. It’s not a treatment that should be administered during an allergic reaction, however. Epinephrine, usually administered via injection, remains the intervention for severe reactions.

As of early 2026, there was no vaccine for Lyme disease available. One candidate vaccine, VLA15, was in later-stage clinical trials. Another designed to provide seasonal protection was licensed to a pharmaceutical company in 2025, and was planned for human clinical trials.

An outline of the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginning of precision medicine.

The company's chemists were attempting to synthesize a substance that could compete with an existing patent for the best clot medicine of that time, hydrastinine. MDMA was the byproduct of that effort.

Among opioids, fentanyl is uniquely adept at crossing the blood-brain barrier—the brain's security fence against harmful substances. This enables a lightning-fast high. It ends just as quickly, sometimes within minutes (where a heroin high lasts hours), and still results in the same withdrawal symptoms.

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

As many as a quarter of MS patients have antibodies in their blood that bind to both a central protein in Epstein-Barr virus and a protein made in the brain and spinal cord that—when attacked—leads to a breakdown of protective nerve fiber insulation. This suggests the immune system's primed to attack the nervous system after mounting a defense against Epstein-Barr.

Recent research scouring blood samples from 134 people with MS, both before and after their diagnosis, found that about seven years before these patients were diagnosed, there was a spike in a protein called myelin oligodendrocyte glycoprotein—indicating disease-associated damage to the protective myelin around nerve fibers.

Our ability to build new myelin sheaths for nerves degrades with age. There have been research advances boosting cells that support these processes and clear away debris from degraded myelin, but not yet any medications to boost myelination itself, which would aid nerve signaling and preserve nerve function.

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.